Dirk Hasenclever is an expert in Hematology at Leipzig University (Germany). As of July 2026, ScienceLeadR ranks Dirk Hasenclever in the top 1% of experts worldwide for Lymphoma. Dirk Hasenclever has authored 183 publications, the most recent in 2026, and is an investigator in 5 clinical trials. SLR score: 625 (community average: 125). How the SLR is computed.

LeadR Profile

Dirk Hasenclever Leipzig University Germany
625 ScienceLeadR Reputation 625
Network Map

Hematology

Subspecialties: Oncology - Critical Care - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1996 - 2026

Source: PubMed

Leipzig University

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 183

Citations

Citations: 15 753 1st author: 8 Last author: 16 Unique author: 2


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Prevalence, pattern and prognosis of lung lesions in pediatric Hodgkin lymphoma.
PMID 42409915 — lung, progression-free survival, hodgkin disease, lymphoma, prevalence, therapeutics, wounds and injuries, prognosis
Sci Rep20260
​EuroNet-PHL-LP1: Complete resection or low-dose chemo for pediatric low-risk nodular lymphocyte-predominant Hodgkin lymphoma.
PMID 42234940 — disease-free survival, lymph nodes, lymphocytes, hodgkin disease, lymphoma, drug therapy, lymph, anthracyclines, therapeutics, chemotherapy
Blood Adv20260
Prevention of surgical site infections in lower limb fracture fixation and elective arthroplasty: a systematic review and meta-analysis of decolonization and skin antisepsis strategies.
PMID 41652612 — skin, arthroplasty, antisepsis, incidence, surgical wound infection, wounds and injuries, fracture fixation, infections, acute care surgery
Antimicrob Resist Infect Control20260
Quantitative Deauville Scoring to Uncover Prognostic Information from 18F-FDG PET-Based Response Assessment: Data from the EuroNet-PHL-C1 Trial.
PMID 40639904 — radiotherapy, lymphoma, fluorodeoxyglucose f18, nuclear medicine, therapeutics
J Nucl Med20250
Publisher Correction: EFFECT of daily antiseptic bathing with octenidine on ICU-acquired bacteremia and ICU-acquired multidrug-resistant organisms: a multicenter, cluster-randomized, double-blind, placebo-controlled, cross-over study.
PMID 40128383 — bacteremia, cross-over studies, anti-infective agents, local, critical care, intensive care units
Intensive Care Med20250

Clinical Studies 5

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 4
Phase 2 1

By status:

Completed 3
Terminated 1
Unknown 1

By type:

Interventional 5

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 1
multicentric5to9 1
multicentricup10 2

Main Topics

Cohort/Consortium Investigators 2

LeadR Networks

Main global connection map